Drug Development

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

A new partnership aims to use tiny, fully human antibodies to shuttle drugs past the blood-brain barrier, a move that could unlock a new era of treatments.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

An inside look at how Chengdu is pairing high-tech industrial might with aggressive global outreach to redefine itself as a critical node in tech and biotech.

New guidelines for ankle arthritis, a condition hitting younger workers hard, expose major gaps in medical research and a market ripe for innovation.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Behind the headlines of cancer breakthroughs lies a booming market for specialized research firms. Discover how CROs are becoming the new engine of oncology innovation.

As lawsuits allege a link between blockbuster weight-loss drugs like Ozempic and irreversible blindness, a critical question emerges: Who guards our health?

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

A new transatlantic partnership leverages AI and a £5.25M philanthropic gift to accelerate the discovery of kinder, more effective treatments for children.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

Caidya's union with Simbec-Orion isn't just another M&A deal. It’s a strategic play to build an end-to-end clinical partner for a complex global market.